Vaccinia virus protein K7 is a virulence factor that alters the acute immune response to infection

Camilla T. O. Benfield, Hongwei Ren, Stuart J. Lucas, Basma Bahsoun and Geoffrey L. Smith

1Department of Pathology, University of Cambridge, Tennis Court Road, Cambridge, CB2 1QP, UK
2Department of Virology, Faculty of Medicine, Imperial College London, St. Mary's Campus, London W2 1PG, UK

Correspondence Geoffrey L. Smith
gls37@cam.ac.uk

Vaccinia virus (VACV) encodes many proteins that antagonize the innate immune system including a family of intracellular proteins with a B-cell lymphoma (Bcl)-2-like structure. One of these Bcl-2 proteins called K7 binds Toll-like receptor-adaptor proteins and the DEAD-box RNA helicase DDX3 and thereby inhibits the activation of NF-κB and interferon regulatory factor 3. However, the contribution of K7 to virus virulence is not known. Here a VACV lacking the K7R gene was constructed and compared with control viruses that included a plaque purified wt (vK7), a revertant with the K7R gene reinserted (vK7-rev) and a frame-shifted virus in which the translational initiation codon was mutated to prevent K7 protein expression (vK7-fs). Data presented show that loss of K7 does not affect virus replication in cell culture or in vivo; however, viruses lacking the K7 protein were less virulent than controls in murine intradermal (i.d.) and intranasal (i.n.) infection models and there was an altered acute immune response to infection. In the i.d. model, vΔK7 induced smaller lesions than controls, and after i.n. infection vΔK7 induced a reduced weight loss and signs of illness, and more rapid clearance of virus from infected tissue. Concomitantly, the intrapulmonary innate immune response to infection with vΔK7 showed increased infiltration of NK cells and CD8+ T-cells, enhanced MHC class II expression by macrophages, and enhanced cytolysis of target cells by NK cells and VACV-specific CD8+ T-cells. Thus protein K7 is a virulence factor that affects the acute immune response to infection.

INTRODUCTION

Vaccinia virus (VACV) is the prototypic member of the genus Orthopoxvirus of the family Poxviridae. VACV was utilized as the vaccine to eradicate smallpox (Fenner et al., 1988), but although VACV induced immunity to Variola virus, the cause of smallpox, the vaccine strains used widely in the eradication campaign, such as Lister and New York City Board of Health, caused significant complication rates that are unacceptable in a modern vaccine (Lane et al., 1969). After smallpox eradication, interest in VACV has remained due to its development as an expression vector for live vaccines against infectious diseases (Panicali et al., 1983; Smith et al., 1983a, b) and cancers (Lathe et al., 1987; Walsh & Dolin, 2011). In addition, VACV is an excellent model system for studying virus–host interactions and further study has been prompted by concern about possible bioterrorism with Variola virus.

VACV is a large, complex virus with a dsDNA genome of about 200 kbp that replicates in the cytoplasm (Moss, 2007) and encodes numerous immunomodulatory proteins that antagonize the innate immune response (Smith et al., 1997; Seet et al., 2003). A subgroup of these immunomodulatory proteins have a B-cell lymphoma (Bcl)-2-like structure. For instance, proteins N1 (Aoyagi et al., 2007; Cooray et al., 2007), B14 (Graham et al., 2008), A52 (Graham et al., 2008), K7 (Kalverda et al., 2009) and F1 (Kvansakul et al., 2008) all have had their crystal structures solved and proteins A46, C6, N2 and B22 are also predicted to be members of this family (Graham et al., 2008; González & Esteban, 2010). One of these proteins, K7, is the subject of this study.

VACV strain Western Reserve (WR) protein K7 is a 17.5 kDa intracellular protein that binds to the DEAD-box...
RNA helicase DDX3, tumour necrosis factor receptor-associated factor 6 (TRAF6) and IL-1 receptor-associated kinase 2 (IRAK2) to inhibit activation of interferon regulatory factor (IRF)3 and NF-κB (Schröder et al., 2008). VACV protein A52 also binds TRAF6 and IRAK2 (Harte et al., 2003), which couple engagement of the IL-1 receptor and Toll-like receptors (TLR) to downstream NF-κB signalling. However, deletion of A52 gave an in vivo phenotype (Harte et al., 2003) despite the presence of K7, indicating these proteins have non-redundant functions. This may be due to the ability of K7 to bind DDX3, which acts as an adaptor for the TBK1 (TANK binding kinase 1)/IKKe (IkappaB kinase epsilon) kinases, which mediate IRF activation, and binds directly to the IFN-β promoter (Schröder et al., 2008; Soulat et al., 2008; Mulhern & Bowie, 2010). K7 interacts with a critical diphenylalanine motif at the N terminus of DDX3 (Oda et al., 2009) using a hydrophobic interaction surface that is conserved among VACV Bcl-2-like proteins (Cooray et al., 2007; Graham et al., 2008; Bahar et al., 2011; Benfield et al., 2011; Maluquer de Motes et al., 2011). Thus, K7 can antagonize both TLR-dependent and -independent IFN-β activation (Schröder et al., 2008).

Despite the well-established molecular mechanism of K7, its role in vivo is unknown. Here, we have constructed a VACV WR strain lacking K7 (vΔK7) and show that this virus is attenuated in both local and systemic murine infection models. In the absence of K7, virus was cleared more rapidly from the lungs after intranasal (i.n.) infection, and, consistent with this, there were enhanced NK cell- and CD8+ T-cell-mediated cytolyis of target cells. Thus, K7 is a virulence factor that affects the acute immune response to infection.

RESULTS

K7 expression occurs early after infection and is conserved among orthopoxviruses

The kinetics of K7 transcription from its natural viral promoter were assessed by Northern blotting on total RNA from WR-infected cells using a K7-specific deoxy-oligonucleotide probe (Fig. 1a). This identified a single band of about 500 bp, consistent with the predicted length of the K7 transcript. The steady state K7 mRNA levels were maximal at 2 h post-infection (p.i.) and thereafter declined, but remained detectable until 12 h p.i. The presence of cytosine arabinoside (AraC), an inhibitor of DNA replication, or cycloheximide (CHX), an inhibitor of protein synthesis, enhanced the level of K7 mRNA at 6 h p.i. compared with untreated cells. This is characteristic of early VACV mRNAs, which are transcribed by the virion-associated DNA-dependent RNA polymerase independent of viral protein synthesis or genome replication (Moss, 2007). To test experimentally whether K7 was expressed by different orthopoxviruses, extracts from cells infected with different VACV or cowpox virus (CPXV) strains were immunoblotted with anti-K7 Ab (Fig. 1b, lower panel). K7 was expressed by all 16 VACV strains (including modified VACV Ankara, MVA) and both CPXV strains (Brighton Red and elephant-pox virus) tested.

To investigate the contribution of K7 to virus replication and virulence, a VACV deletion mutant lacking the K7R gene (vΔK7) was constructed by transient dominant selection (Falkner & Moss, 1990). A plaque purified wt virus (vK7) was isolated from the same intermediate virus. In addition, a revertant virus with the K7R gene reinserted into vΔK7 (vK7-rev), and a ‘frame-shifted’ virus in which an additional nucleotide was introduced into the K7 translation initiation codon (vK7-fs) were also constructed as controls. PCR analysis using primers for the K7R locus revealed that the K7R locus of these viruses was as
predicted, and digestion of purified virus genomic DNA separately with HindIII, XhoI and NcoI showed that the HindIII K band was altered in size in vΔK7 as expected, but no other genomic alterations were detectable (Fig. S1, available in JGV Online, and data not shown). Immunoblotting with extracts of cells infected by these viruses confirmed that K7 was expressed by vK7 and vK7-rev but not by vΔK7 or vK7-fs (Fig. 1c). As a control for infection, immunoblotting with mAb AB1.1 directed against the VACV structural protein D8 showed that D8 was expressed by all viruses (Fig. 1c).

The subcellular localization of K7 was assessed using biochemical fractionation of infected HeLa cells followed by anti-K7 immunoblotting (Fig. 2a). K7 was detected within the cytoplasmic fraction of cells infected with either wt virus or vK7-HA, which expresses N-terminally haemagglutinin (HA) epitope-tagged K7 from its natural locus (Methods). Immunofluorescence on fixed cells confirmed the cytoplasmic distribution of HA in vK7-HA-infected cells, compared with only background staining in cells infected with vΔK7 (Fig. 2b).

**K7 is non-essential for replication but contributes to VACV virulence**

The replication of vΔK7 in cell culture was measured after infection at high m.o.i. and found to be indistinguishable from controls (Fig. 3a). Similarly, the plaque size of vΔK7 on BSC-1 cells was indistinguishable from control viruses, indicating that K7 was not needed for normal cell-to-cell spread (Fig. 3b). Hence K7 is non-essential for VACV replication in cell culture.

To assess whether K7 contributed to VACV virulence in the intradermal (i.d.) murine model of infection (Tscharke & Smith, 1999), vΔK7 or control viruses were inoculated i.d. in the ear pinna of C57BL/6 mice and the size of the resulting lesions was measured daily (Fig. 4). Infection with vΔK7 induced a smaller lesion compared with vK7 and vK7-rev, and these differences were statistically significant (two-tailed Student’s t-test, P < 0.05) over days 7–18. Next the virulence of vΔK7 was compared with that of control

---

**Fig. 2.** K7 is localized to the cytoplasm. (a) HeLa cells were mock-infected or infected with the indicated viruses at 10 p.f.u. per cell for 16 h. Nuclear and cytoplasmic fractions were then separated and analysed by SDS-PAGE and immunoblotting with the indicated antibodies. A fourfold greater proportion of the nuclear fraction was loaded than for the cytoplasmic fraction. The position of molecular size markers are shown in kDa. (b) HeLa cells were infected with vK7-HA or vΔK7 at 5 p.f.u. per cell for 5 h. After fixation and permeabilization, cells were stained with mouse anti-HA followed by anti-mouse Alexa Fluor 546 (red)-conjugated secondary antibody and viewed by confocal microscopy. Bar, 20 μm.

**Fig. 3.** K7 is non-essential for VACV replication and spread in cell culture. (a) BSC-1 cells were infected with indicated viruses at 10 p.f.u. per cell and were harvested at the indicated times. Cells were disrupted by freeze–thawing and sonication and infectious virus was titrated by plaque assay. Data shown are mean ± SD of 2 separate experiments. (b) Scatter plots with means (horizontal bars) of plaque sizes of vK7, vΔK7 and vK7-rev in BSC-1 cells infected with 50–100 p.f.u. per well and incubated for 2, 3 or 4 days. Plaque sizes (n = 15) were measured using ImagePro 4.0 analysis software.
viruses by i.n. infection of mice (Williamson et al., 1990). vΔK7 induced significantly less weight loss (Fig. 5a) and fewer signs of illness (Alcamí & Smith, 1992) (Fig. 5b) than the K7-expressing viruses vK7 and vK7-rev. An additional control virus, vK7-fs, containing an extra nucleotide to disrupt the translational start codon of the K7 ORF, behaved equivalently to vΔK7 (Fig. 5a, b). This confirmed that the K7 protein was responsible for the attenuated phenotype. Using a slightly lower virus dose (5 × 10⁶ p.f.u.), vK7 and vK7-rev viruses caused 25% reduction in body weight, while vΔK7 caused no weight loss or signs of illness (data not shown). This attenuation correlated with significantly lower viral titre in the infected lungs of vΔK7-infected mice compared with controls at days 5 and 8 p.i. (Fig. 5c). At day 2 p.i. all virus titres were increased above that of the inoculation dose but were equivalent between all groups showing that K7 is not needed for replication in vivo. This confirmed that subsequent differences were due to more efficient clearance of vΔK7 rather than replicative differences and suggested that vΔK7 might induce a more robust antiviral immune response. This was investigated by assessing immune cell infiltration into infected lungs.

**K7 alters leukocyte recruitment following i.n. VACV infection**

The kinetics and composition of leukocyte recruitment into the lung following i.n. inoculation of VACV WR was reported previously (Reading & Smith, 2003a). To determine the impact of K7 on leukocyte recruitment, infiltrating cells were analysed by flow cytometry at several times p.i. with vΔK7, vK7 or vK7-rev (Fig. 6). In mice infected with vΔK7 there was no statistically significant change in the overall number of infiltrating cells harvested from lung tissue compared to the controls, although there appeared to be a slight increase at day 6 (data not shown). However, a higher proportion of these cells expressed the
common leukocyte antigen CD45 on day 6 compared with the controls (Fig. 6a). At this time there was a substantial increase in infiltrating T-cells suggesting that the overall increase was dominated by T-cells (Fig. 6b). Furthermore, after vΔK7 infection there were approximately twice as many activated macrophages in both the alveolar space (bronchoalveolar lavage, BAL) and the lung tissue on day 6 compared with controls, as shown by high surface expression of MHC class II (Fig. 6c). Concomitantly, there were fewer neutrophils (as a proportion of total cells recovered) in the lung tissue of vΔK7-infected mice relative to controls at days 3 and 6 p.i. (Fig. 6d).

**vΔK7 induces enhanced intrapulmonary NK- and CD8+ T-cell-dependent cytotoxicity**

Since NK and CD8+ cytotoxic T-lymphocytes (CTL) play crucial roles in controlling poxvirus infections *in vivo* (Bukowski *et al.*, 1983; Xu *et al.*, 2004; Parker *et al.*, 2007; Martínez *et al.*, 2010), these cell populations were analysed in the lung 6 days after i.n. infection. There were significantly more NK cells in the lungs of vΔK7-infected mice, both as a proportion of total lymphocytes (Fig. 7a) and in absolute numbers (data not shown). In addition, a significantly higher proportion of infiltrating T-cells were...
CD8\(^+\) CTL, rather than CD4\(^+\) cells, following vΔK7 infection compared with vK7 or vK7-rev (Fig. 7b). To assess the functional consequence of the enhanced recruitment of NK cells, NK-sensitive Yac-1 target cells were labelled with 51Cr and incubated with single-cell suspensions of homogenized lungs. A significantly higher level of NK-mediated target lysis was seen (for effector:target ratios of 50 and 100; Student’s \(t\)-test, \(P<0.05\)) for mice infected with vΔK7 compared with control viruses (Fig. 7c). Similarly, enhanced killing of 51Cr-loaded VACV-infected P815 target cells by CD8\(^+\) CTL was observed for vΔK7 at an effector:target ratio of 100 (Fig. 7d). These data demonstrate that removal of K7 from VACV increases the overall pulmonary NK- and CTL-dependent cytotoxic responses after infection.

**DISCUSSION**

This report provides characterization of the contribution of VACV WR protein K7 to virus replication, spread and virulence and demonstrates that K7 is a virulence factor that affects the acute immune response to infection. A virus lacking K7 replicated normally in cell culture (Fig. 3) and
Vaccinia virus protein K7 is a virulence factor

**in vivo** (Fig. 5c d 2), but was less virulent than control viruses in both i.d. (Fig. 4) and i.n. (Fig. 5a, b) infection models and induced stronger pulmonary NK and CD8+ T-cell responses (Fig. 7). Consistent with this, infectious virus was cleared from lungs more rapidly after infection with vΔK7 than control viruses (Fig. 5c).

K7 is a member of the Bcl-2 family of VACV proteins (Graham et al., 2008; Kalverda et al., 2009; González & Esteban, 2010) and shares several features with other proteins of this family. These proteins are characterized by inhibiting either innate immune signalling pathways (N1, B14, A52, A46, C6) and/or apoptosis (N1 and F1), and N1 inhibiting either innate immune signalling pathways (N1, Esteban, 2010) and shares several features with other proteins of this family. These proteins are characterized by inhibiting either innate immune signalling pathways (N1, B14, A52, A46, C6) and/or apoptosis (N1 and F1), and N1 (Kotwal et al., 1989; Bartlett et al., 2002; Cooray et al., 2007; Maluquer de Motes et al., 2011), B14 (Chen et al., 2006, 2008), A52 (Harte et al., 2003), A46 (Stack et al., 2005), C6 (Garcia-Arriaza et al., 2011; Unterholzner et al., 2011; Sumner et al., 2013) and K7 (this report) are all non-essential for virus replication but mutant viruses lacking each protein separately all show attenuated phenotypes in vivo. Therefore, these proteins have non-redundant functions.

Characterization of K7R gene transcription by Northern blotting showed a single 500 bp mRNA whose expression was maximal at 2 h p.i. (Fig. 1a), consistent with the transcription start site and immediate-early kinetics assigned to K7R in genome-wide expression studies (Assarsson et al., 2008; Yang et al., 2010). The K7 protein was predominantly cytoplasmic during virus infection (Fig. 2a, b), in contrast to the nucleus and cytoplasmic distribution seen following plasmid transfection (Schröder et al., 2008). K7 shows a high level of conservation between orthopoxviruses [Fig. 1b and Schröder et al. (2008)] and has a defined molecular mechanism (Schröder et al., 2008; Kalverda et al., 2009; Oda et al., 2009), making it attractive for further study. This report shows that deletion of a single cytoplasmic protein that blocks NF-κB activation and IFN-β induction can alter both virus virulence and the primary immune response to infection, promoting a Th1 (type 1 T-helper cell)-skewed response, despite the presence of other VACV inhibitors of NF-κB and IRF3.

The attenuation of vΔK7 in vivo was not due to a defect in virus replication because both virus yield and plaque size in cell culture (Fig. 3), and replication shortly after infection in vivo (Fig. 5c) were equivalent with control viruses. The two murine infection models used here are distinct and complementary for assessing VACV virulence. The i.d. infection of ear pinnae mimics dermal vaccination: only a localized lesion develops and immunity against VACV challenge is induced (Tscharke & Smith, 1999; Tscharke et al., 2002; Jacobs et al., 2006). On the other hand, i.n. infection leads to acute pneumonitis followed by dissemination to secondary sites of infection (including brain, spleen and liver) and systemic signs of illness (Williamson et al., 1990; Alcamí & Smith, 1992; Reading & Smith, 2003a). VACV inoculation by the two different routes induces different inflammatory responses (Reading & Smith, 2003a), and approximately half of the single gene mutants which have been tested in both models exhibit a phenotype in only one model (Tscharke et al., 2002). Moreover, deletion of VACV immunomodulators does not lead to predictable phenotypic consequences, and there are examples where virulence was enhanced rather than reduced (Alcamí & Smith, 1992, 1996; Reading et al., 2003b; Clark et al., 2006). Notably, deletion of K7 results in attenuation of WR in both infection models.

The immune response to infection by vΔK7 was analysed by flow cytometry and this revealed that different cell populations were recruited to the infected tissue (Figs. 6 and 7). Infection (i.n.) with vΔK7 led to significant increases in total T-cell influx, in CD8+ T-cells (expressed as a percentage of total T-cells), in NK cell recruitment and in MHC class II expression by macrophages in the lung parenchyma or bronchoalveolar space (relative to control infections). Together, these alterations indicate that loss of K7 induced a more robust Th1-cell-mediated immune response. The most marked differences in cellular composition were seen at day 6 p.i. (Fig. 6). At this time, the net cytotoxic activity of pulmonary NK and CD8+ T-cells was significantly increased (Fig. 7), and viral titres in the lungs of vΔK7-infected mice were significantly reduced from 5 days p.i. compared with control virus infections (Fig. 5c). These data are consistent with a recent report showing that CD8+ T-cells (not CD4+ T-cells or antibodies) are necessary and sufficient for recovery from primary WR infection in the murine i.n. model used here (Goulding et al., 2012).

The targeted deletion of immunomodulators from VACV has the potential to improve the utility of VACV as a vaccine by enhancing safety and/or immunogenicity. For instance, with VACV proteins that are secreted from the infected cell, it was shown that deletion of VACV gene A41L encoding a secreted CC chemokine binding protein (Ng et al., 2001; Bahar et al., 2008) enhanced the primary CD8+ T-cell responses to infection although virulence was enhanced slightly (Clark et al., 2006). Removal of a secreted IL-1β binding protein, which is encoded by several VACV strains including MVA (Alcamí & Smith, 1992; Spriggs et al., 1992; Blanchard et al., 1998), also created a more immunogenic MVA strain (Staib et al., 2005; Cottingham et al., 2008). The immunogenicity of VACV has also been improved by removal of genes encoding other secreted proteins that bind IL-18 (Smith et al., 2000; Reading & Smith, 2003b; Falivene et al., 2012) or type I IFN (Colománcini et al., 1995; Symons et al., 1995; Gómez et al., 2012) or type II IFN (Alcamí & Smith, 1995; Mossman et al., 1995; Gómez et al., 2012).

Similarly, VACV intracellular proteins also modulate the inflammatory response. For instance, deletion of the steroid biosynthetic enzyme 3β-hydroxysteroid dehydrogenase enhanced IFN-γ production and VACV-specific CD8+ CTL (Moore & Smith, 1992; Reading et al., 2003a). In addition, deletion of N1 (Jacobs et al., 2008), B14 (Chen et al., 2006) and C16 (Fahy et al., 2008) also altered the...
inflammatory response to infection. This study demonstrates that removal of the intracellular protein K7, which has a known structure and mechanism of action, simultaneously reduced the virulence and enhanced the immunogenicity of VACV despite the presence of other NF-κB, IRF3 and IFN antagonists. Both these phenotypic changes are desirable for VACV-based vaccines. While VACV WR provides a well-characterized and virulent virus strain in which to test phenotypes, it is not a useful strain. MVA is a promising candidate for VACV-vectored vaccines (Sutter & Staib, 2003) and although it lacks many immunomodulators (Antoine et al., 1998; Blanchard et al., 1998), it expresses an identical version of K7 to that studied here [Fig. 1b and Schröder et al. (2008)]. Our report indicates that deletion of K7 is a promising strategy for enhancing the immunogenicity and utility of VACV as a vaccine.

**METHODS**

**Cell culture.** BSC-1 and L929 cells were grown in Dulbecco’s modified Eagle’s medium (DMEM; Gibco) supplemented with 10 % FBS (Harlan Seralab) and penicillin/streptomycin (50 μg ml⁻¹; Gibco). HeLa cells were maintained in modified Eagle’s medium (Gibco) containing 10 % FBS, non-essential amino acids (Sigma Gibco). HeLa cells were grown in RPMI 1640 (Gibco) containing 10 % FBS and antibiotics as above. All cells were cultured at 37 °C in a humidified 5 % CO₂ atmosphere.

**Antibodies.** Anti-K7 polyclonal antibody (Schröder et al., 2008) and the mouse mAb AB1.1 against VACV protein D8 (Parkinson & Smith, 1994) were described previously. Mouse anti-lamins A and C (Abcam ab8984), mouse anti-tubulin (Millipore 05-829) and mouse anti-HA (Covance MMS-101P) were also used.

**Construction of recombinant VACVs.** The following oligonucleotide primers were used for PCR: 039U (5’-AACCTTCTGATT-CACCATCTTCTTCATGGC-3’); 039D (5’-TAGATCAGAAGTGTTAAGTTTAC-3’); 039N (5’-CCCTATATCATCGAC-TATCTCACAAAGACAGATC-3’); and 039C (5’-GTGAGATAG-TCTGATATGGGTCTTGAGCC-3’).

Using 039U and 039D, the K7R ORF with 339 bp of upstream and 323 bp of downstream flanking sequence was amplified from VACV WR genomic DNA by PCR. The flanking sequences alone were amplified using 039U and 039N and 039C and 039D, respectively, and then spliced together via the overlapping sequences of 039N and 039C (italicized) in a second amplification with 039U and 039D. PCR products were cloned into the EcoRI site of plasmid pSJH7 (Hughes et al., 1991) to produce pSJH7-K7 and pSJH7-ΔK7. The plasmid pSJH7-K7-fs was constructed by site-directed mutagenesis using pSJH7-K7 as the template and contained an extra adenine within the translation initiation codon (i.e. ATAG). The plasmid pSJH7-K7-HA was constructed with an N-terminal HA tag in-frame with the K7R ORF. All plasmids were sequenced to ensure their fidelity. CV-1 cells were infected with VACV strain WR and transfected with pSJH7-ΔK7 and vAK7 was isolated by transient dominant selection as described previously (Falkner & Moss, 1990), along with a wt isolate (vK7) derived from the same intermediate virus. Similarly, vAK7-infected cells were transfected with pSJH7-K7 to create a revertant virus, vK7-rev, with pSJH7-K7-fs to create vK7-fs, or with pSJH7-K7-HA to create the vK7-HA virus. Virus infectivity and plaque morphology were assessed by plaque titration on BSC-1 cells.

**Northern blotting.** L929 cells were infected with VACV WR at 10 p.f.u. per cell and, at various times p.i., total RNA was collected using Trizol. Cycloheximide (CHX; Sigma Aldrich, UK), at 100 μg ml⁻¹, or cytosine arabinoside (AraC; Sigma Aldrich, UK), at 40 μg ml⁻¹, was added where indicated during the 1 h adsorption period and for 6 h thereafter. Total RNA (10 μg) for each sample was denatured by glyoxalization immediately prior to electrophoresis in a 1.4 % agarose gel and 0.5 M sodium phosphate (pH 7) running buffer. RNA was transferred by capillary transfer onto Hybond-N⁺ membrane, UV cross-linked to the membrane and then de-glyoxylated using boiling 20 mM Tris/HCl pH 8. The blot was then pre-hybridized in ULTRAhyb-Oligo Hybridization buffer (Ambion) for 30 min at 42 °C before 10⁻⁶ counts min⁻¹ ml⁻¹ of 32P-labelled deoxy-oligonucleotide probe (5’-GGTGTCTCTGTGGCTAGCTTGGCACAATCT-3’) was added and hybridized overnight at 42 °C to detect K7R mRNA. The probe was prepared by 5’-end labelling 10 pmol of oligonucleotide with 20 pmol γ-32P ATP using T4 polynucleotide kinase (NEB). Following hybridization, the membrane was washed in 2 × SSC (sodium-sodium citrate buffer, 0.3M sodium chloride, 0.03M sodium citrate)/0.5 % SDS twice for 30 min each at 42 °C before exposing it to X-ray film. To allow sizing, RNA markers were run on the gel, stained with ethidium bromide and then aligned with the membrane.

**Confocal microscopy.** HeLa cells were grown on glass coverslips, fixed using 4 % paraformaldehyde (Electron Microscope Science, Germany) in 250 mM HEPES/PBS and permeabilized using 0.1 % Triton X-100 (Sigma Aldrich). The cells were then pre-incubated in blocking buffer (10 % FBS in PBS) for 1 h, incubated with primary antibody for 1 h and then incubated with anti-mouse Alexa Fluor 546-conjugated secondary antibodies (Invitrogen) for 30 min. Coverslips were mounted in DAPI and examined with a Zeiss LSM5 Pascal scanning confocal microscope using Zeiss LSM software.

**Cellular fractionation.** Cells were washed twice with ice-cold lysis buffer (20 mM HEPES pH 7.8, 0.5 mM DTT, 0.5 mM MgCl₂ supplemented with Roche protease inhibitor tablets) prior to separation of nuclear and cytoplasmic fractions as previously described (Unterholzner et al., 2011).

**Immunoblotting.** Cell lysates were prepared and proteins detected as previously described (Bartlett et al., 2002).

**Virus growth curves.** BSC-1 cells were infected with each virus in duplicate at 10 p.f.u. per cell, and single cycle virus growth was determined as previously described (Chen et al., 2006).

**Plaque size assay.** Plaque size was measured microscopically on BSC-1 monolayers as previously described (Doccel et al., 2010).

**Murine infection models.** For i.d. inoculations, female, 6–8 week old C57BL/6 mice were infected as described previously (Tscharke & Smith, 1999; Tscharke et al., 2002). For i.n. infection, female, 6–8 week old BALB/c mice were inoculated under anaesthetic with the indicated virus dose in 20 μl of PBS supplemented with 0.1 % BSA (or mock-infected with the same diluent), and monitored as described previously (Williamson et al., 1990; Alcamí & Smith, 1992). Inocula were routinely titrated by plaque assay to confirm the dose administered. Experiments were conducted under the appropriate licence and regulations stipulated by the Animals (Scientific Procedures) Act 1986, UK Government. All in vivo data shown are from one representative experiment, and all experiments were performed at least twice.

**Determination of lung viral titres.** The lungs were homogenized and washed through a 70 μm nylon mesh using DMEM and 10% FBS. Cells were then frozen and thawed three times, and sonicated.
thoroughly to liberate intracellular virus. Infectious virus was titrated in duplicate by plaque assay on BSC-1 cell monolayers.

**Cell preparation and staining for flow cytometry.** Broncho-alveolar lavage (BAL) fluids were obtained, and lungs were prepared as described previously (Reading & Smith, 2003a; Chen et al., 2006; Clark et al., 2006). Fluorophore-antibody conjugates (used at recommended dilutions) were: allophycocyanin (APC)-rat anti-mouse CD45, FITC-anti-mouse CD3, APC- rat anti-mouse CD4 (BD), phycoerythrin (PE)-rat anti-mouse CD8a (BD), PE-anti-mouse I-A/I-E (MHC II) (BD), FITC-anti-mouse CD11b (Serotec), PE-anti-mouse Ly6G (BD) and PE-Cy5.5-anti-mouse F4/80 (Caltag). Stained cells were washed, fixed using 1% paraformaldehyde in PBS and analysed on a BD FACS caliber.

**Chromium-release cytotoxicity assay.** NK cell cytotoxicity and VACV-specific CTL activity was assayed with a standard $^5$Cr-release assay using the previously described protocol (Clark et al., 2006). NK-mediated lysis was tested on uninfected YAC-1 cells, while VACV-infected P815 cells (H-2d, mastocytoma) were used as targets for VACV-specific CTL lysis. The percentage of specific $^5$Cr release was calculated as specific lysis=[(experimental release–spontaneous release)/(total detergent release–spontaneous release)]×100. The spontaneous release values were always <10% of total lysis.

**Statistical analysis.** Unless otherwise stated, data were analysed using a two-tailed Student’s $t$-test. Unless otherwise stated, datasets were compared with the t-test using the previously described protocol (Clark et al., 2006). NK-mediated lysis was tested on uninfected YAC-1 cells, while VACV-infected P815 cells (H-2d, mastocytoma) were used as targets for VACV-specific CTL lysis. The percentage of specific $^5$Cr release was calculated as specific lysis=[(experimental release–spontaneous release)/(total detergent release–spontaneous release)]×100. The spontaneous release values were always <10% of total lysis.

**ACKNOWLEDGEMENTS**

This work was supported by grants from the Wellcome Trust and the Medical Research Council of the UK. G. L. S is a Wellcome Trust Principal Research Fellow. We thank members of our laboratory for critical reading of the manuscript.

**REFERENCES**

Alcamí, A. & Smith, G. L. (1992). A soluble receptor for interleukin-1 beta encoded by vaccinia virus: a novel mechanism of virus modulation of the host response to infection. *Cell* 71, 153–167.

Alcamí, A. & Smith, G. L. (1995). Vaccinia, cowpox, and camelpox viruses encode soluble gamma interferon receptors with novel broad species specificity. *J Virol* 69, 4633–4639.

Alcamí, A. & Smith, G. L. (1996). A mechanism for the inhibition of fever by a virus. *Proc Natl Acad Sci U S A* 93, 11029–11034.

Antoine, G., Scheiflinger, F., Dorner, F. & Falkner, F. G. (1998). The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. *Virology* 244, 365–396.

Aoyagi, M., Zhai, D., Jin, C., Aleshin, A. E., Stec, B., Reed, J. C. & Liddington, R. C. (2007). Vaccinia virus N1L protein resembles a B cell lymphoma-2 (Bcl-2) family protein. *Protein Sci* 16, 118–124.

Assarsson, E., Greenbaum, J. A., Sundström, M., Schaffer, L., Hammond, J. A., Pasquetto, V., Oseroff, C., Hendrickson, R. C., Leffkowitz, E. J. & other authors (2008). Kinetic analysis of a complete poxvirus transcriptome reveals an immediate-early class of genes. *Proc Natl Acad Sci U S A* 105, 2140–2145.

Bahr, M. W., Kenyon, J. C., Putz, M. M., Abrescia, N. G., Pease, J. E., Wise, E. L., Stuart, D. I., Smith, G. L. & Grimes, J. M. (2008). Structure and function of A41, a vaccinia virus chemokine binding protein. *PLoS Pathog* 4, e5.

Bahar, M. W., Graham, S. C., Chen, R. A., Cooray, S., Smith, G. L., Stuart, D. I. & Grimes, J. M. (2011). How vaccinia virus has evolved to subvert the host immune response. *J Struct Biol* 175, 127–134.

Bartlett, N., Symons, J. A., Tscharke, D. C. & Smith, G. L. (2002). The vaccinia virus N1L protein is an intracellular homodimer that promotes virulence. *J Gen Virol* 83, 1965–1976.

Benfield, C. T., Mansur, D. S., McCoy, L. E., Ferguson, B. J., Bahar, M. W., Oldring, A. P., Grimes, J. M., Stuart, D. I., Graham, S. C. & Smith, G. L. (2011). Mapping the IkappaB kinase beta (IKKbeta)-binding interface of the B14 protein, a vaccinia virus inhibitor of IKKbeta-mediated activation of nuclear factor kappaB. *J Biol Chem* 286, 20727–20735.

Bennink, J. R., Yewdell, J. W., Smith, G. L. & Moss, B. (1986). Recognition of cloned influenza virus hemagglutinin gene products by cytotoxic T lymphocytes. *J Virol* 57, 786–791.

Blanchard, T. J., Alcamí, A., Andrea, P. & Smith, G. L. (1998). Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. *J Gen Virol* 79, 1159–1167.

Bukowski, J. F., Woda, B. A., Habu, S., Okumura, K. & Welsh, R. M. (1983). Natural killer cell depletion enhances virus synthesis and virus-induced hepatitis in vivo. *J Immunol* 131, 1531–1538.

Chen, R. A., Jacobs, N. & Smith, G. L. (2006). Vaccinia virus strain Western Reserve protein B14 is an intracellular virulence factor. *J Gen Virol* 87, 1451–1458.

Chen, R. A., Ryzhakov, G., Cooray, S., Randow, F. & Smith, G. L. (2008). Inhibition of IkappaB kinase by vaccinia virus virulence factor B14. *PLoS Pathog* 4, e22.

Clark, R. H., Kenyon, J. C., Bartlett, N. W., Tscharke, D. C. & Smith, G. L. (2006). Deletion of gene A41L enhances vaccinia virus immunogenicity and vaccine efficacy. *J Gen Virol* 87, 29–38.

Colomonici, O. R., Domanski, P., Sweltzer, S. M., Larner, A. & Buller, R. M. (1995). Vaccinia virus B18R gene encodes a type I interferon-binding protein that blocks interferon alpha transmembrane signaling. *J Biol Chem* 270, 15974–15978.

Cooray, S., Bahar, M. W., Abrescia, N. G., McVey, C. E., Bartlett, N. W., Chen, R. A., Stuart, D. I., Grimes, J. M. & Smith, G. L. (2007). Functional and structural studies of the vaccinia virus virulence factor N1 reveal a Bcl-2-like anti-apoptotic protein. *J Gen Virol* 88, 1656–1666.

Cottingham, M. G., Andersen, R. F., Spencer, A. J., Saurya, S., Furze, J., Hill, A. V. & Gilbert, S. C. (2008). Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA). *PLoS One* 3, e1638.

Doceul, V., Hollinshead, M., van der Linden, L. & Smith, G. L. (2010). Repulsion of superinfecting virions: a mechanism for rapid virus spread. *Science* 327, 873–876.

Fahy, A. S., Clark, R. H., Glyde, E. F. & Smith, G. L. (2008). Vaccinia virus protein C16 acts intracellularly to modulate the host response and promote virulence. *J Gen Virol* 89, 2377–2387.

Falivene, J., Del Médico Zajac, M. P., Pascutti, M. F., Rodríguez, A. M., Maeto, C., Perdigueró, B., Gómez, C. E., Esteban, M., Calamante, G. & Gherardi, M. M. (2012). Improving the MVA vaccine potential by deleting the viral gene coding for the IL-18 binding protein. *PLoS ONE* 7, e32220.

Falkner, F. G. & Moss, B. (1990). Transient dominant selection of recombinant vaccinia viruses. *J Virol* 64, 3108–3111.

Fenner, F., Anderson, D. A., Arita, I., Jezek, Z. & Ladnyi, I. D. (1988). *Smallpox and its Eradication*. Geneva: World Health Organization.

García-Arriaza, J., Nájera, J. L., Gómez, C. E., Tewabe, N., Sorzano, C. O., Calandra, T., Roger, T. & Esteban, M. (2011). A candidate HIV/
AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses. PLoS ONE 6, e24244.

Gómez, C. E., Perdiguero, B., Nájera, J. L., Sorzano, C. O., Jiménez, V., González-Sanz, R. & Esteban, M. (2012). Removal of vaccinia virus genes that block interferon type I and II pathways improves adaptive and memory responses of the HIV/AIDS vaccine candidate NYVAC-C in mice. J Virol 86, 5026–5038.

González, J. M. & Esteban, M. (2010). A poxvirus Bcl-2-like gene family involved in regulation of host immune response: sequence similarity and evolutionary history. Virol J 7, 59.

Gouling, J., Bogue, R., Tahlilani, V., Croft, M. & Salek-Ardakani, S. (2012). CD8 T cells are essential for recovery from a respiratory vaccinia virus infection. J Immunol 189, 2432–2440.

Graham, S. C., Bahar, M. W., Cooray, S., Chen, R. A., Whalen, D. M., Abrescia, N. G., Alderton, D., Owens, R. J., Stuart, D. I., & other authors (2008). Vaccinia virus proteins A52 and B14 share a Bcl-2-like fold but have evolved to inhibit NF-kappaB rather than apoptosis. PLoS Pathog 4, e1000128.

Harte, M. T., Haga, I. R., Maloney, G., Gray, P., Reading, P. C., Bartlett, N. W., Smith, G. L., Bowie, A. & O'Neill, L. A. (2003). The poxvirus protein A52R targets Toll-like receptor signaling complexes to suppress host defense. J Exp Med 197, 343–351.

Hughes, S. J., Johnston, L. H., de Carlos, A. & Smith, G. L. (1991). Vaccinia virus encodes an active thymidylate kinase that complements the vaccinia enzyme: a new type of virus virulence factor. Proc Natl Acad Sci U S A 88, 4927–4931.

Jacobs, N., Chen, R. A., Gubser, C., Najarro, P. & Smith, G. L. (2006). Intradermal immune response after infection with vaccinia virus. J Gen Virol 87, 1157–1161.

Kalverda, A. P., Thompson, G. S., Vogel, A., Schröder, M., Bowie, A. G., Khan, N. R. & Homans, S. W. (2009). Poxvirus K7 protein adopts a Bcl-2 fold: biochemical mapping of its interactions with human DEAD box RNA helicase DDX3. J Mol Biol 385, 843–853.

Kotwal, G. J., Hugín, A. W. & Moss, B. (1989). Mapping and insertional mutagenesis of a vaccinia virus gene encoding a 13,800-Da secreted protein. Virology 171, 579–587.

Kvansakul, M., Yang, H., Fairlie, W. D., Czabotar, P. E., Fischer, S. F., Perugini, M. A., Huang, D. C. & Colman, P. M. (2008). Vaccinia virus anti-apoptotic F1L is a novel Bcl-2-like domain-swapped dimer that binds a highly selective subset of BH3-containing death ligands. Cell Death Differ 15, 1564–1571.

Lane, J. M., Ruben, F. L., Neff, J. M. & Millar, J. D. (1969). Complications of smallpox vaccination, 1968. N Engl J Med 281, 1201–1208.

Lathe, R., Kienny, M. P., Gerlinger, P., Clermont, P., Guizani, I., Cuzin, F. & Chambon, P. (1987). Tumour prevention and rejection with recombinant vaccinia. Nature 326, 878–880.

Mackett, M., Smith, G. L. & Moss, B. (1982). Vaccinia virus: a selectable eukaryotic cloning and expression vector. Proc Natl Acad Sci U S A 79, 7415–7419.

Malouquer de Motes, C., Cooray, S., Ren, H., Almeida, G. M., McGourty, K., Bahar, M. W., Stuart, D. I., Grimes, J. M., Graham, S. C. & Smith, G. L. (2011). Inhibition of apoptosis and NF-kB activation by vaccinia protein N1 occur via distinct binding surfaces and make different contributions to virulence. PLoS Pathog 7, e1002430.

Martinez, J., Huang, X. & Yang, Y. (2010). Direct TLR2 signaling is critical for NK cell activation and function in response to vaccinia viral infection. PLoS Pathog 6, e1000811.

Moore, J. B. & Smith, G. L. (1992). Steroid hormone synthesis by a vaccinia enzyme: a new type of virus virulence factor. EMBO J 11, 1973–1980.

Moss, B. (2007). Poxviridae; the viruses and their replication. In Fields Virology, 5th edn, pp. 2903–2946. Edited by D. M. Knipe, P. M. Howley, D. E. Griffin, R. A. Lamb, M. A. Martin, B. Roizman & S. E. Straus. Philadelphia: Lippincott Williams & Wilkins.

Mossman, K., Upton, C., Buller, R. M. & McFadden, G. (1995). Species specificity of ectromelia virus and vaccinia virus interferon-gamma binding proteins. Virology 208, 762–769.

Mulhern, O. & Bowie, A. G. (2010). Unexpected roles for DEAD-box protein 3 in viral RNA sensing pathways. Eur J Immunol 40, 933–955.

Ng, A., Tscharek, D. C., Reading, P. C. & Smith, G. L. (2001). The vaccinia virus A41L protein is a soluble 30 kDa glycoprotein that affects virus virulence. J Gen Virol 82, 2095–2105.

Oda, S., Schröder, M. & Khan, A. R. (2009). Structural basis for targeting of human RNA helicase DDX3 by poxvirus protein K7. Structure 17, 1528–1537.

Osman, M., Kubo, T., Gill, J., Neipel, F., Becker, M., Smith, G., Weiss, R., Gazzard, B., Boshoff, C. & Gotch, F. (1999). Identification of human herpesvirus 8-specific cytotoxic T-cell responses. J Virol 73, 6136–6140.

Panicali, D. & Paoletti, E. (1982). Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. Proc Natl Acad Sci U S A 79, 4927–4931.

Panicali, D., Davis, S. W., Weinberg, R. L. & Paoletti, E. (1983). Construction of live vaccines by using genetically engineered poxviruses: biological activity of recombinant Vaccinia virus expressing influenza virus hemagglutinin. Proc Natl Acad Sci U S A 80, 5364–5368.

Parker, A. K., Parker, S., Yokoyama, W. M., Corbett, J. A. & Buller, R. M. (2007). Induction of natural killer cell responses by ectromelia virus controls infection. J Virol 81, 4070–4079.

Parkinson, J. E. & Smith, G. L. (1994). Vaccinia virus gene A36R encodes a Mr(4) 30–50 K protein on the surface of extracellular enveloped virus. Virology 204, 376–390.

Reading, P. C. & Smith, G. L. (2003a). A kinetic analysis of immune mediators in the lungs of mice infected with vaccinia virus and comparison with intradermal infection. J Gen Virol 84, 1973–1983.

Reading, P. C. & Smith, G. L. (2003b). Vaccinia virus interleukin-18-binding protein promotes virulence by reducing gamma interferon production and natural killer and T-cell activity. J Virol 77, 9960–9968.

Reading, P. C., Moore, J. B. & Smith, G. L. (2003a). Steroid hormone synthesis by vaccinia virus suppresses the inflammatory response to infection. J Exp Med 197, 1269–1278.

Reading, P. C., Symons, J. A. & Smith, G. L. (2003b). A soluble chemokine-binding protein from vaccinia virus reduces virus virulence and the inflammatory response to infection. J Immunol 170, 1435–1442.

Schröder, M., Baran, M. & Bowie, A. G. (2008). Viral targeting of DEAD box protein 3 reveals its role in TBK1/IKKepsilon-mediated IRF activation. EMBO J 27, 2147–2157.

Seet, B. T., Johnston, J. B., Brunetti, C. R., Barrett, J. W., Everett, H., Cameron, C., Sypula, J., Nazarian, S. H., Lucas, A. & McFadden, G. (2003). Poxviruses and immune evasion. Annu Rev Immunol 21, 377–423.

Smith, G. L., Mackett, M. & Moss, B. (1983a). Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen. Nature 302, 490–493.
Smith, G. L., Murphy, B. R. & Moss, B. (1983b). Construction and characterization of an infectious vaccinia virus recombinant that expresses the influenza hemagglutinin gene and induces resistance to influenza virus infection in hamsters. *Proc Natl Acad Sci U S A* **80**, 7155–7159.

Smith, G. L., Symons, J. A., Khanna, A., Vanderplasschen, A. & Alcamı´ , A. (1997). Vaccinia virus immune evasion. *Immunol Rev* **159**, 137–154.

Smith, V. P., Bryant, N. A. & Alcamı´ , A. (2000). Ectromelia, vaccinia and cowpox viruses encode secreted interleukin-18-binding proteins. *J Gen Virol* **81**, 1223–1230.

Soulat, D., Bürckstäümmer, T., Westermayer, S., Goncalves, A., Bauch, A., Stefanovic, A., Hantschel, O., Bennett, K. L., Decker, T. & Superti-Furga, G. (2008). The DEAD-box helicase DDX3X is a critical component of the TANK-binding kinase 1-dependent innate immune response. *EMBO J* **27**, 2135–2146.

Spriggs, M. K., Hruby, D. E., Maliszewski, C. R., Pickup, D. J., Sims, J. E., Buller, R. M. & VanSlyke, J. (1992). Vaccinia and cowpox viruses encode a novel secreted interleukin-1-binding protein. *Cell* **71**, 145–152.

Stack, J., Haga, I. R., Schröder, M., Bartlett, N. W., Maloney, G., Reading, P. C., Fitzgerald, K. A., Smith, G. L. & Bowie, A. G. (2005). Vaccinia virus protein A46R targets multiple Toll-like-interleukin-1 receptor adaptors and contributes to virulence. *J Exp Med* **201**, 1007–1018.

Staib, C., Kisling, S., Erfle, V. & Sutter, G. (2005). Inactivation of the viral interleukin beta receptor improves CD8⁺ T-cell memory responses elicited upon immunization with modified vaccinia virus Ankara. *J Gen Virol* **86**, 1997–2006.

Sumner, R. P., Ren, H. & Smith, G. L. (2013). Deletion of immunomodulator C6 from vaccinia virus strain Western Reserve enhances virus immunogenicity and vaccine efficacy. *J Gen Virol* **94**, 1121–1126.

Sutter, G. & Staib, C. (2003). Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery. *Curr Drug Targets Infect Disord* **3**, 263–271.

Symons, J. A., Alcamı´ , A. & Smith, G. L. (1995). Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity. *Cell* **81**, 551–560.

Tschirke, D. C. & Smith, G. L. (1999). A model for vaccinia virus pathogenesis and immunity based on intradermal injection of mouse ear pinnae. *J Gen Virol* **80**, 2751–2755.

Tschirke, D. C., Reading, P. C. & Smith, G. L. (2002). Dermal infection with *Vaccinia virus* reveals roles for virus proteins not seen using other inoculation routes. *J Gen Virol* **83**, 1977–1986.

Unterholzner, L., Sumner, R. P., Baran, M., Ren, H., Mansur, D. S., Bourke, N. M., Randow, F., Smith, G. L. & Bowie, A. G. (2011). Vaccinia virus protein C6 is a virulence factor that binds TBK-1 adaptor proteins and inhibits activation of IRF3 and IRF7. *PLoS Pathog* **7**, e1002247.

Walsh, S. R. & Dolin, R. (2011). Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors. *Expert Rev Vaccines* **10**, 1221–1240.

Williamson, J. D., Reith, R. W., Jeffrey, L. J., Arrand, J. R. & Mackett, M. (1990). Biological characterization of recombinant vaccinia viruses in mice infected by the respiratory route. *J Gen Virol* **71**, 2761–2767.

Xu, R., Johnson, A. J., Liggitt, D. & Bevan, M. J. (2004). Cellular and humoral immunity against vaccinia virus infection of mice. *J Immunol* **172**, 6265–6271.

Yang, Z., Bruno, D. P., Martens, C. A., Porcella, S. F. & Moss, B. (2010). Simultaneous high-resolution analysis of vaccinia virus and host cell transcriptomes by deep RNA sequencing. *Proc Natl Acad Sci U S A* **107**, 11513–11518.

http://vir.sgmjournals.org